Valuation: Endonovo Therapeutics Inc

Market Cap 27.73L 23.99L 22.4L 20.55L 38.65L 26Cr 39.26L 2.63Cr 1.03Cr 13Cr 1.04Cr 1.02Cr 44Cr P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 99.26L 85.86L 80.18L 73.56L 1.38Cr 94Cr 1.41Cr 9.41Cr 3.69Cr 47Cr 3.73Cr 3.65Cr 156.54Cr EV / Sales 2021
11,24,21,804x
EV / Sales 2022 7,86,89,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2012
Investor Relations Contact - 01/05/2014
Corporate Officer/Principal 70 01/03/2022
Director TitleAgeSince
Chairman 61 01/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
+8.49%+23.38%+65.44%+104.90% 6.29TCr
+1.25%+2.44%+32.55%+72.63% 5.43TCr
+2.07%+2.68%-16.47%-5.57% 2.29TCr
-1.44%+31.77%+18.87%+494.10% 2.87TCr
+10.83%+21.32%+45.03%+2.02% 2.16TCr
+6.50%+7.56%+38.20%-21.33% 1.78TCr
-3.88%+20.98%+201.07%+350.94% 1.65TCr
+6.20%+12.16%+28.51%+629.05% 1.55TCr
+2.85%+1.68%+44.21%+166.27% 1.31TCr
Average +3.64%+7.42%+50.82%+199.22% 2.82TCr
Weighted average by Cap. +4.04%+9.95%+47.51%+165.68%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.96 0.1 0.69 0.27 3.49 0.27 0.27 11.53 0.14 0.12 0.11 0.1 0.19 12.88 0.19 1.28 0.5 6.46 0.51 0.5 21.35
Net income -31.05L -26.86L -25.08L -23.01L -43.27L -30Cr -43.96L -2.94Cr -1.15Cr -15Cr -1.17Cr -1.14Cr -49Cr -1.85Cr -1.6Cr -1.49Cr -1.37Cr -2.57Cr -175.83Cr -2.62Cr -18Cr -6.87Cr -88Cr -6.94Cr -6.79Cr -291.35Cr
Net Debt 70.95L 61.37L 57.31L 52.58L 98.89L 68Cr 1Cr 6.72Cr 2.64Cr 34Cr 2.66Cr 2.61Cr 111.89Cr 71.53L 61.87L 57.78L 53.01L 99.7L 68Cr 1.01Cr 6.78Cr 2.66Cr 34Cr 2.69Cr 2.63Cr 112.81Cr
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-